Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
VRTX
VRTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VRTX News
CASGEVY Shows Transformative Potential in Children with Sickle Cell Disease and Beta Thalassemia
Jun 11 2026
Newsfilter
Analysis of JEPI ETF Trading Dynamics
Jun 11 2026
NASDAQ.COM
Biopharma Investment Comparison: Kyverna vs. Vertex
Jun 08 2026
Fool
Analyzing Biopharmaceutical Investment Choices
Jun 08 2026
NASDAQ.COM
CRISPR Therapeutics Faces Stagnant Stock Despite Promising Pipeline
Jun 08 2026
Fool
Vertex Announces Phase 3 Data for ALYFTREK in Cystic Fibrosis
Jun 05 2026
Newsfilter
Viatris Sales Trends Improve, Valuation Potential Rises
Jun 04 2026
CNBC
Analysis of Healthcare Stock Recovery Opportunities
Jun 04 2026
NASDAQ.COM
Investment Opportunities in Healthcare Stocks
Jun 04 2026
Fool
Vertex's PDUFA Date Set for Povetacicept Approval on November 30, 2026
Jun 01 2026
Newsfilter
Investment Choices in Gene Editing Technology
May 31 2026
Yahoo Finance
Avaí Bio Achieves Milestone in α-Klotho Cell Bank Development
May 28 2026
Newsfilter
Seeking Alpha's Quant Ratings Upgrades and Downgrades Analysis
May 27 2026
seekingalpha
Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam
May 26 2026
Fool
Analysis of Gene Editing Industry Prospects
May 26 2026
NASDAQ.COM
CRISPR Therapeutics Shows Promising Upside Potential
May 11 2026
Fool
Show More News
